我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
批准总数
监管机构
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无批准数据
- GSK has agreed to acquire RAPT Therapeutics for $2.2 billion to gain control of ozureprubart, a potentially best-in-class anti-IgE antibody for food allergy protection. - Ozureprubart offers potential for less frequent dosing every 12 weeks compared to current standard-of-care therapy requiring injections every 2-4 weeks. - The acquisition addresses significant unmet medical need, with over 17 million people diagnosed with food allergies in the US and more than 1.3 million suffering severe reactions. - Phase IIb trial results are expected in 2027, with phase III trials planned for both adult and pediatric populations.
